Cargando…

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA

Biomarkers may be useful when deciding which nonsmall cell lung cancer (NSCLC) patients may benefit from adjuvant chemotherapy following complete resection and which chemotherapeutic agents may be used preferably in individual patients in order to maximise survival. A literature search covering the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallerek, Sandra, Sørensen, Jens Benn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2015
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487808/ https://www.ncbi.nlm.nih.gov/pubmed/26028645 http://dx.doi.org/10.1183/16000617.00005814

Ejemplares similares

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada, Naoko, et al.
Publicado: (2020)

Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC
por: Yu, Hongliang, et al.
Publicado: (2020)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
por: Tanizaki, Junko, et al.
Publicado: (2023)

Adjuvant chemotherapy for completely resected IIA–IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice
por: Désage, Anne-Laure, et al.
Publicado: (2022)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

Update on adjuvant therapy in completely resected NSCLC patients
por: Lim, Jeong Uk, et al.
Publicado: (2021)

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
por: Zhang, Shu-Ling, et al.
Publicado: (2023)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers
por: Kilvaer, Thomas K., et al.
Publicado: (2015)

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
por: Garitaonaindia, Yago, et al.
Publicado: (2023)

Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
por: Heineman, David J., et al.
Publicado: (2017)

Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection
por: Akazawa, Yuki, et al.
Publicado: (2017)

Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2016)

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study
por: Wisnivesky, Juan P, et al.
Publicado: (2011)

Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy
por: Shukuya, Takehito, et al.
Publicado: (2022)

Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC
por: Agrawal, Vishesh, et al.
Publicado: (2017)

Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial
por: Park, Cheol-Kyu, et al.
Publicado: (2022)

Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database
por: Wang, Xia, et al.
Publicado: (2021)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Efficacy of adjuvant chemotherapy after complete resection of pulmonary metastasis from colorectal cancer
por: Okazaki, Yuki, et al.
Publicado: (2021)

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
por: Brascia, Debora, et al.
Publicado: (2020)

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
por: Buhl, Ida Kappel, et al.
Publicado: (2018)

Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?
por: Weder, Walter, et al.
Publicado: (2021)

Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer
por: Lei, Tao, et al.
Publicado: (2016)

Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
por: Lowczak, Anna, et al.
Publicado: (2020)

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy
por: Yang, Hui, et al.
Publicado: (2021)

Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Dan, Aravot, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iakf4400o0jq86dm4f10q9vk27